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Background: Nonalcoholic fatty liver disease (NAFLD), which represents metabolic abnormality and
reﬂects extra visceral fat deposition, has been shown to be a threat to public health and associated
with cardiovascular risks. However, data regarding the differences in clinical presentation and
related metabolic abnormalities in the aging group population remained scarce in the Taiwanese
population.
Methods: We subsequently examined 8,658 subjects participating general health evaluation in Mackay
Memorial hospital from 2003 to 2007. Baseline characteristics, anthropometrics, medical history, and
biochemical markers were all collected. Abdominal ultrasonography was performed in all subjects. Two
estimated cardiovascular risk scores were calculated according to criteria of the U.S. National Cholesterol
Education Program Adult Treatment Panel III as metabolic score and Framingham risk score. Univariate
logistic regression model was used to examine whether the baseline characteristics, anthropometrics,
histories, and biochemical markers were independently associated with NAFLD from various age groups
(young vs. aging groups) classiﬁed by 60 years of age. Respective receiver operating characteristic curves
(ROC) with area under the curve were generated to test the capability of both cardiovascular risk scores
in NAFLD discrimination from different age groups.
Results: Totally 7,204 subjects (mean age: 44.5 11 years, 36% female) were ﬁnally enrolled in our study.
Subjects with NAFLDwere observed to have high bodyweight, bodymass index, and circumferential waist
and signiﬁcantly abnormal biochemical markers accompanying worsening lipid proﬁles when compared
with thosewithout NAFLD in both the young and aging group populations (all p< 0.001) although alkaline
phosphatase, total cholesterol, and low-density lipoprotein did not show signiﬁcant differences with and
without NAFLD in the aging grouppopulation. Diabetes history remained a strong independent predictor of
NAFLD in both young and aging groups (odds ratio: 3.3, p< 0.001 vs. 2.51, p¼ 0.014). The predictionmodel
by using different cardiovascular risk scores yielded ameaningful ROC value of 0.82 (young group) and 0.71
(aging group) (both p< 0.001) for metabolic score with ROC value of 0.67 (young group) and 0.52 (aging
group) for Framingham risk score (p< 0.001 vs. 0.408, respectively).
Conclusion: The prevalence of NAFLD demonstrated a bimodal distribution with age in different genders.
Although baseline characters and biochemical markers were demonstrated to be potential screening
tools in detecting such clinical abnormality, they actually exerted diverse capabilities in the prediction ofthe Mackay Memorial Hospital, Taipei, Taiwan. All contributing authors claim no conﬂict of interest with regard to the
te of Health Care Organization Administration, College of Public Health, National Taiwan University, No. 17, Shu-Chow
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Predictive Biomarkers for NAFLD 185NAFLD in the different age groups. Traditional cardiovascular risk scores were less effective in predicting
NAFLD in the aging group population.
Copyright  2010, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
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The worldwide prevalence and incidence of nonalcoholic fatty
liver disease (NAFLD) is on an upward trend. According to previous
epidemiologic studies, there was a high correlation between NAFLD
and metabolic syndrome although gender and racial differences
may exist.1 Therefore, NAFLD patients may have had comorbidities
including obesity, hyperlipidemia, insulin resistance, and abnormal
blood pressure. If these patients do not enact early weight control
and dietary modiﬁcation, they are at an increased risk of
developing type II diabetes mellitus, hypertension (HTN), and
subsequent cardiovascular diseases.2,3 In addition, the coexistence
of NAFLD with abnormal liver function can lead to liver ﬁbrosis and
even cirrhosis or carcinoma.4,5 Overall, the pathologies associated
with NAFLD appear to increase patient mortality and are of
signiﬁcant health concern. However, it has been found that NAFLD
ﬁbrosis at an early stage is reversible with the peak incidence of
NAFLD occurs in those aged 40e59 years1. Early and appropriate
diagnosis, control of relevant risk factors, and timely
pharmacologic treatment can effectively prevent subsequent
morbidities resulting from NAFLD.6
At present, liver biopsy remains to be the “gold standard” for
establishing clinical diagnosis for NAFLD; however, the bias of this
invasive liver biopsy can be as high as 24%e37% and have a higher
diagnostic risk.7 Thus, the studies to ﬁnd out the low-cost and
noninvasive diagnostic tool for NAFLD is ensued.
According to the World Health Organization criteria for obesity
and the Adult Treatment Panel III (ATP III) for metabolic syndrome,8
body mass index (BMI), waist circumference, alanine
aminotransferase (ALT), and aspartate aminotransferase (AST) are
the clinical variables and biochemical markers associated with the
risk factors for NAFLD.9,10 Metabolic syndrome is exacerbated in
patients with NAFLD.11,12 Effective monitoring of these risk factors,
together with weight loss and changing lifestyle habits, such as
drinkingalcohol, can thuseffectivelydecreaseNAFLDandreduce the
risk of developing metabolic syndromes.13,14 Some studies have
investigated the risk factors and common serum biochemical
markers in NAFLD.15e17
Although the established screening method linking metabolic
syndrome and NAFLD by appropriate markers had been fully
addressed, data regarding the risk factors and metabolic compo-
nents for the aging groupwith NAFLD are less well documented.18,19
In this study, we investigate the differences in the clinical presen-
tation, associated risks, and related metabolic abnormalities in the
aging group with NAFLD.2. Materials and Methods
2.1. Subjects
The data were derived from 8,658 subjects attending general
health examination performed between 2003 and 2007 at Health
Evaluation Center, Mackay Memorial Hospital, which is currently
a tertiary teaching center in Taipei, Taiwan, including medical
histories for chronic illnesses, structured questionnaires based on
the evaluation for Asian populations as recommended by theWorld
Health Organization (28),20 physical examination including systolicanddiastolic bloodpressures, anthropometrics, biochemicalmarker
levels, and abdominal ultrasonography (US). Subjects who had
excess alcohol usage, hepatitis B or C conﬁrmed by serologic tests
and those with other known etiologies of liver diseases, heart
failure (New York Heart Association classiﬁcation >3), and end-
stage renal disease were excluded. Venous sampling for blood
tests were performed for all subjects, followed by a detailed
physical examination and abdominal US by three hepatology
specialists. After exclusion, a total of 7,559 subjects were analyzed.
All subjects gave informed consent for the use of their clinical and
laboratory results for research purposes. This study was approved
by local ethical institution board committee (09MMHIS043).
2.2. Laboratory instruments
Sample collection and analysis were performed in a standard
laboratory,with international accreditation (ISO-15189). All subjects
were requested to fast for more than 8 hours before venous blood
sampling with BD Vacutainer SSTTM (Becton Dickinson, Franklin
Lakes, NJ, USA) sample collection tube. Sample collection and
treatment principles were based on the standard requirements
dictated by the Clinical Laboratory Standards Institute guidelines
(Specimen Choice, Collection, and Handling; Approved Guideline
H18-A3). To ensure accuracy, the samples were tested in their
original tubes to avoid sample mix-up and testing was completed
in 1 day. A Hitachi 7170 automatic analyzer (Hitachi Corp., Hitachi-
naka Ibaraki, Japan) was used to measure fasting glucose (hexoki-
nase method), total cholesterol (T-Chol), triglycerides (TG), g-
glutamyl transpeptidase (g-GT), uric acid (UA), alkaline phosphatase
(ALP) (enzymatic colorimetric test), AST, and ALT (enzymatic
method), low-density lipoprotein (LDL) cholesterol (homogenous
enzymatic colorimetric assay), blood urea nitrogen, and creatinine
(kinetic colorimetric assay). Renal function represented as esti-
mated glomerular ﬁltration ratewas assessed by usingModiﬁcation
of Diet in Renal Disease formula as previously described.21 Quality
control and instrument operation were in accordance with
standard procedures dictated by Clinical Laboratory Standards
Institute guidelines. Sample analysis was performed after quality
control. Samples were performed in triplicate, and assay
measurements were conﬁrmed to be in the linear range with an
internal standard.
2.3. Estimated cardiovascular risks
The metabolic score (MS) was calculated and presented as the
numbers of abnormal items of the National Cholesterol Education
Program Panel III criteria (ATP III) with score 0 represents absence
of any abnormal metabolic components, whereas score 5 repre-
sents the subjects with all ﬁve abnormal metabolic components.22
The Framingham risk score (FRS) was assessed as previously
described method.23
2.4. Liver US examination
The US examinations were performed by a trained hepatology
specialist with a Toshiba Nemio SSA-550A instrument (Toshiba,
Tochigi-ken, Japan). The operator was completely blinded to other
C.-C. Liu et al.186laboratory results. Liver pathology was graded semiqualitatively as
absent (0), mild (1), moderate (2), severe (3), and cirrhotic (4)
according to the level of echoes arising from the hepatic paren-
chyma, liver-kidney difference in echo amplitude, echo penetration
into the deep portion of the liver, and clarity of liver blood vessel
structure.24,25 Moreover, because the interpretation of fatty liver by
abdominal ultrasound may tend to be subjective, and to avoid the
statistical bias, we deﬁned subjects with at least moderate-degree
fatty liver disease as signiﬁcant fatty liver disease (NAFLD) in this
study.
2.5. Statistical analysis
Continuous data were expressed as the mean and standard
deviation with categorical data expressed as the frequency and
proportion of occurrence in all subjects. Differences of baseline
demographics between groups were tested by Student t test with
categorical data analyzed by c2 or Fisher exact test as appropriate.
Wilcoxon-rank sum test was used to estimate the trend of all
continuous data and ordinal variables across all ordered groups.
Univariate logistic regression model was used to determine the
independent factors in the prediction of fatty liver with individual
odds ratio, signiﬁcance (p value) and 95% conﬁdence interval
reported. Receiver operating characteristic curves with effective
area under the curve (AUC) was calculated to evaluate the validity
of estimated cardiovascular risks including MS and FRS in the
logistic discrimination of signiﬁcant fatty liver change as a predic-
tive model.
All data were analyzed by commercialized software Stata 8.0
package (Stata Corp., College Station, TX, USA). The signiﬁcance of pFig. 1. The percentages and distribution of subjects with different extent of fatty liver change
in patients 60 years old or older and those younger than 60 years old (B). A bimodal distribu
cardiovascular risk scores (both MS and FRS) were observed to correlate with higher degree f
FRS¼ Framingham risk score.level (a value) for all analysis was two sided with a value of <0.05
considered being statistically signiﬁcant.
3. Results
Among the 8,658 cases, ultrasound examination was available in
8,281 cases. Totally 7,204 subjectswith amean age of 44.511 years
(36% female)wereﬁnally included inour studycohort after exclusion
for those with incomplete data acquisition, viral hepatitis, known
etiologies of liver diseases, and thosewith excess alcohol usage. Data
from US classiﬁed 4,221 studies (58.6%) as normal, 2,143 studies
(29.8%) as trivial fatty liver changes, 735 (10%) asmoderate, 87 (1%) as
severe-degree fatty liver changes, and another 18 studies (<1%) as
cirrhotic. Thus, the prevalence of NAFLD in our study was 11.7% (840
subjects) with 11.6% in the younger (771 subjects) and 12.7% (69
subjects) in the aging groups, respectively. Fig. 1 illustrates that with
increasing age, the prevalence of fatty liver disease with various
degrees actually increased, with a peak incidence occurring in the
age of 40e50 years in the whole study population. In addition, the
absolute numbers dropped obviously in subjects older than 60
years. When divided into different genders, a bimodal distribution
was observed with an earlier peak incidence occurred around
middle age (40e50 years) in the male gender and a late peaking
pattern in the female gender (after 50e60 years). Estimated
cardiovascular risk scores were observed to increase toward
a signiﬁcant trend across the ordered extent of fatty liver changes
in the whole population (Z score: 31.7 for MS vs. 12.1 for FRS, both
p< 0.001, respectively).
Table 1 lists the baseline variables and associated biochemical
markers. It revealed that subjects younger than 60 years withs over different age groups and genders (A) and the percentages with fatty liver changes
tion of NAFLD with age was demonstrated over different genders (C). Higher estimated
atty liver changes (D). NAFLD¼ nonalcoholic fatty liver disease; MS¼metabolic scores;
Table 1
Baseline characters and biochemical data in our study.
Age groups
Younger than 60 yr p 60 yr or older p Younger than 60 yr 60 yr or older p
Disease groups Disease groups Disease groups
Normal
(n¼ 5,885)
NAFLD
(n¼ 771)
Normal
(n¼ 479)
NAFLD
(n¼ 69)
All subjects
(n¼ 6,656)
All subjects
(n¼ 548)
Age (yr) 42.5 8.9 44.3 8.2 <0.001 65.8 5.3 65.7 5.3 0.87 42.8 8.8 65.9 5.3 <0.001
SBP (mmHg) 116.4 15.2 127.1 15.9 <0.001 130.7 17.2 132.5 14.8 0.42 117.7 15.7 131.1 16.9 <0.001
BH (cm) 165.7 8.3 168.4 7.9 <0.001 161.5 7.9 164.8 8.4 0.002 166 8.3 162 8.1 <0.001
BW (kg) 63.7 11.1 79.2 13 <0.001 63.2 10 74.1 12.1 <0.001 65.5 12.4 64.5 11 0.07
Waist (cm) 78.6 9.3 91.7 9.2 <0.001 84.1 8.5 92.6 10.1 <0.001 80.1 10.2 85.1 9.2 <0.001
Waist-hip ratio (%) 0.85 0.08 0.93 0.07 <0.001 0.9 0.07 0.95 0.08 <0.001 0.86 0.08 0.91 0.08 <0.001
BMI (kg/m2) 23.1 2.9 27.8 3.7 <0.001 24.1 2.9 27.1 2.9 <0.001 23.6 3.4 24.5 3.1 <0.001
Chronic illnesses
Hypertension Hx (%) 11 25 <0.001 42 52 0.219 13 44 <0.001
Diabetes Hx (%) 4 11 <0.001 16 32 0.011 4 17 <0.001
Hyperlipidemia Hx (%) 4 13 <0.001 13 17 0.534 5 14 <0.001
Fasting glucose (mg/dL) 93.8 15.4 107.9 31.9 <0.001 105 26.4 119.7 39.1 <0.001 95.5 18.7 106.5 28.4 <0.001
Postprandial glucose
(mg/dL)
102.8 32.5 126.7 56.4 <0.001 135.3 54.3 163.8 72.5 <0.001 105.6 36.8 138.5 57.2 <0.001
AST (IU/L) 22 8.5 31 14.7 <0.001 25.3 10.8 28.5 11.2 0.039 23.1 9.9 25.6 10.8 <0.001
ALT (IU/L) 26 19.3 51.2 32.2 <0.001 26.9 21.2 39.1 33.3 <0.001 28.9 22.6 28.1 23 0.47
AST/ALT 1 0.35 0.67 0.19 <0.001 1.05 0.27 0.85 0.24 <0.001 0.97 0.35 1.03 0.28 <0.001
g-GT (IU/L) 28.9 25 46.4 34.1 <0.001 30.2 22 50 71.3 <0.001 31.1 27.1 32.4 32.2 0.38
ALP (IU/L) 65.4 17.7 70.8 17.2 <0.001 73.8 24.7 69.7 16.8 0.257 66 17.7 73.4 23.9 <0.001
Cholesterol (mg/dL) 190.1 33.3 202.1 34.1 <0.001 197.9 33.9 203 32.8 0.299 191.4 33.5 198.2 33.7 <0.001
LDL (mg/dL) 121.8 31.1 133.1 31.9 <0.001 129.5 32 134 26.9 0.358 123.1 31.4 129.9 31.5 <0.001
TG (mg/dL) 110.2 74.8 197 154.2 <0.001 122.9 74.8 162.4 73.8 <0.001 120.1 92.1 126.9 75 0.115
UA (mg/dL) 5.9 1.5 7 1.6 <0.001 6.3 1.5 6.4 1.6 0.504 6 1.6 6.3 1.5 <0.001
eGFR (%) 91.5 16.6 89.8 17.9 0.008 77.1 17.7 79.9 19 0.275 91.3 16.8 77.4 18 <0.001
NAFLD¼ nonalcoholic fatty liver disease; SBP¼ systolic blood pressure; BH¼ body height; BW¼ body weight; BMI¼ body mass index; Hx¼ history; AST¼ aspartate
aminotransferase; ALT¼ alanine aminotransferase;. ALP¼ alkaline phosphatase; g-GT¼ g-glutamyl transpeptidase; LDL¼ low-density lipoprotein; TG¼ triglycerides;
UA¼ uric acid; eGFR¼ estimated glomerular ﬁltration rate.
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diabetes and hyperlipidemia, although these differences were less
obvious in. In addition, all biochemical markers showed
signiﬁcant (p< 0.001) differences between NAFLD and non-
NAFDL groups in the young group, whereas ALP (p¼ 0.257), T-
Chol (p¼ 0.299), LDL (p¼ 0.358), and UA (p¼ 0.504) showed no
signiﬁcant differences in the aging group. There was a marginal
difference for AST (p¼ 0.039), whereas the remaining six
variables including fasting and postprandial glucose level, ALT,
AST, g-GT, and TG were highly signiﬁcant between groups
(p< 0.001) in subjects older than 60 years. Fig. 2 demonstrated
that MS was increased in an ordered fashion relating to the
severity of fatty liver changes in both the younger (Z score: 36.91,
p< 0.001) and that aging group (Z score: 8.67, p< 0.001),
whereas FRS did not show such a trend in the aging group (Z
score: 17.64, p< 0.001 vs. 1.69, p¼0.09, respectively).
With the univariate logistic regression model, Table 2 shows
that male gender, all the baseline anthropometrics, medical
histories, and biochemical markers were signiﬁcantly associated
with NAFLD in the younger group (all p< 0.001), whereas male
gender, HTN and hyperlipidemia history, and some biochemical
markers fasting glucose between 100 and 126, ALP, T-Chol, UA,
and estimated glomerular ﬁltration rate were not independently
associated with NAFLD with AST and postprandial glucose
between 140 and 200 showed a borderline predictive signiﬁcance
(p¼ 0.05 and 0.08, respectively) in the aging group.
Table 3 and Fig. 3 show selected values for the AUC, sensitivity,
speciﬁcity, and threshold cutoff points in the discrimination of fatty
liver by estimated cardiovascular risk scores (MS and FRS) for both
younger (0.82 for MS vs. 0.67 for FRS, p< 0.001) and the aging
group generated from receiver operating characteristic curve
(0.71 for MS, p< 0.001; 0.52 for FRS, p¼ 0.408, respectively). For
the detection of NAFLD, the MS of three had a sensitivity of60.8%, speciﬁcity of 84.2% for the younger group and a sensitivity
of 68.9%, speciﬁcity of 62.3% for the aging group, respectively, and
the FRS of 11 had a sensitivity of 21.9%, speciﬁcity of 94.4% for
the younger group and a sensitivity of 57.6%, speciﬁcity of 52.4
for the aging group, respectively.
4. Discussion
Three important messages are demonstrated in our study. The
ﬁrst, an earlier peak in the incidence of NAFLDwas observed inmen
around 40e60 years, whereas the peak was delayed inwomen. The
second, baseline anthropometrics identiﬁed fatty liver disease in
different age groups as well although some biochemical markers
were less signiﬁcant for prediction in the aging group. The third, the
traditional cardiovascular risk scores by using MS seemed to
predict the existence of NAFLD better than by using FRS in both
groups, but for FRS, it is better for those younger than 60 years.
NAFLD is a result of abnormal hepatocellular metabolism possibly
resulting from abnormal higher nutritional load. The speciﬁc
etiologies include disturbances of hepatic lipid metabolism, excess
lipid and glucose from the diet, high free fatty acids in the blood,
and a decreased ability to oxidize and dissociate neutral lipids and
fatty acids.26 Subsequent excess liver TG synthesis, accumulation of
excess visceral fat tissue, and blocked hepatic lipoprotein synthesis
and excretion were then observed with insulin resistance as a key
and central factor. It thus has a substantial overlapping with
metabolic syndrome.27 To prevent the progression from fat tissue
inﬁltration, steatosis to ﬁbrosis, steps toward an aggressive risk
factor control as early as possible may thus be important. Among
these subjects, those with a BMI >25 account for 56%e79% of the
NAFLD population and nearly 30% NAFLD subjects had abnormal
metabolism.28 Regardless of BMI, central obesity seemed to be an
important determinant.29 In our study, waist circumference, BMI,
Fig. 2. The metabolic score, but not the Framingham Risk Score, increases signiﬁcantly parallel with the severity of the fatty liver changes (0¼ normal, 1¼ trivial/mild,
2¼moderate, and 3¼ severe/cirrhotic) for the both groups.
C.-C. Liu et al.188and body weight all were higher in the NAFLD group compared
with non-NAFLD group irrespective of age. Histories of HTN,
diabetes, and hyperlipidemia were linked to NAFLD more closely
in the younger group.
The diagnostic accuracy for NAFLD via US is approximately
33%.6,30 In contrast, between 53% and 83% of NAFLD diagnoses are
determined by serologic tests.7 Prevalence of NAFLD varied widely
between Western and Eastern countries, ranging from 30% to 40%
in the Western to as low as 10% in some Asian studies,7,20,22,31
and the reasons may be related to the different lifestyles and diet
habits.7,28 In Taiwan, Chen et al.32 ever reported the prevalence of
NAFLD of about 11.5%, which is quite close to our observationTable 2
Univariate logistic regression analysis in the prediction of NAFLD
Variables Younger than 60 yr
OR p 95% CI
Gender (male) 3.4 <0.001 2.778797
BMI (kg/m2) 1.58 <0.001 1.533648
<25 1.0 e e
25, <30 8.0 <0.001 6.598499
30 51.6 <0.001 38.51351
BW (kg) 1.12 <0.001 1.109215
Waist (cm) 1.18 <0.001 1.163045
<80/90 1.0 e e
80/90 7.09 <0.001 6.016821
Waist-hip ratio (%) 1.17 <0.001 1.154667
Hypertension Hx (%) 2.71 <0.001 2.096928
Diabetic Hx (%) 3.3 <0.001 2.265492
Hyperlipidemia Hx (%) 3.4 <0.001 2.416886
Fasting glucose (mg/dL) 1.03 <0.001 1.023243
<100 1.0 e e
100, <126 3.05 <0.001 2.564108
126 5.34 <0.001 4.189267
Postprandial glucose (mg/dL) 1.01 <0.001 1.009451
<140 1.0 e e
140, <200 3.27 <0.001 2.424889
200 1.47 <0.001 1.250291
AST (IU/L) 1.07 <0.001 1.060908
ALT (IU/L) 1.04 <0.001 1.034532
AST/ALT 0.01 <0.001 0.005120
g-GT (IU/L) 1.02 <0.001 1.014335
ALP (IU/L) 1.02 <0.001 1.011328
Cholesterol (mg/dL) 1.01 <0.001 1.007973
LDL (mg/dL) 1.01 <0.001 1.008306
TG (mg/dL) 1.01 <0.001 1.007758
UA (mg/dL) 1.51 <0.001 1.437289
eGFR (%) 0.99 0.008 0.988738
NAFLD¼ nonalcoholic fatty liver disease; OR¼ odds ratio; CI¼ conﬁdence interval; BW
ferase; ALT¼ alanine aminotransferase; ALP¼ alkaline phosphatase; g-GT¼ g-glutamyl
eGFR¼ estimated glomerular ﬁltration rate.(11.7%). Several previous studies disputed the signiﬁcant
relationship between the age, gender, and the prevalence of
NAFLD.1,7 Age as an independent risk of developing a more severe
NAFLD or hepatic ﬁbrosis has been proved, with advancing age
linked to an increased risk of death.31 In our study, men
outnumbered women in the incidence of NAFLD, and this was
observed to be an independent risk of fatty liver change. This is
compatible to most previous studies and that published from
Asian-Paciﬁc series.1,7,22 As with the study by Shen et al.30
relating to the general population from Shanghai, we observed
a bimodal age distribution in different genders with a peak
prevalence of NAFLD in men occurred earlier (around 40e6060 yr or older
OR p 95% CI
e4.153922 1.1 0.648 0.6572716e1.962426
e1.630786 1.41 <0.001 1.27904e1.545817
1.0 e e
e9.62655 5.1 <0.001 2.730565e9.391024
e69.24442 12.7 <0.001 5.077115e31.89569
e1.127048 1.1 <0.001 1.069868e1.127751
e1.19099 1.12 <0.001 1.079967e1.164475
1.0 e e
e8.360767 3.16 <0.001 1.758916e5.690708
e1.189453 1.08 <0.001 1.035057e1.129717
e3.490136 1.5 0.221 0.7835586e2.871515
e4.793517 2.51 0.014 1.207576e5.222816
e4.785637 1.32 0.535 0.5470305e3.194767
e1.031169 1.01 0.001 1.005397e1.020348
1.0 e e
e3.625751 1.06 0.851 0.5657288e1.994032
e6.812833 2.42 0.004 1.321509e4.429239
e1.013384 1.01 0.002 1.002565e1.011289
1.0 e e
e4.422324 1.91 0.08 0.9265022e3.941125
e1.71932 2.21 0.006 1.256832e3.898384
e1.076283 1.02 0.05 1.000019e1.041195
e1.041515 1.01 0.006 1.004083e1.024594
e0.011723 0.03 <0.001 0.0079186e0.122781
e1.019953 1.01 0.009 1.003511e1.025011
e1.019505 0.99 0.248 0.9762754e1.006227
e1.012387 1 0.299 0.9960998 e1.012806
e1.013676 1 0.357 0.9948824e1.014332
e1.00952 1.01 0.001 1.002215e1.008645
e1.585626 1.06 0.504 0.887722e1.274413
e0.998301 1.01 0.275 0.9929672e1.025124
¼ body weight; BMI¼ body mass index; Hx¼ history; AST¼ aspartate aminotrans-
transpeptidase; LDL¼ low-density lipoprotein; TG¼ triglycerides; UA¼ uric acid;
Table 3
The sensitivity, speciﬁcity, and cutoff from different estimated cardiovascular risks in the prediction of NAFLD
Younger than 60 yr 60 yr or older
Score Sensitivity (%) Speciﬁcity (%) Correctly classiﬁed (%) Score Sensitivity (%) Speciﬁcity (%) Correctly classiﬁed (%)
Metabolic score Metabolic score
1 96.21 38.20 45.25 1 95.56 13.26 22.7
2 86.57 65.25 67.84 2 86.67 40.35 45.66
3 60.76 84.21 81.36 3 68.89 62.25 63.01
4 34.94 95.22 87.90 4 44.44 85.30 80.61
5 9.81 99.38 88.51 5 4.44 98.27 87.50
Framingham risk score Framingham risk score
2 86.48 23.76 31.13 2 87.88 10.24 19.16
3 79.34 39.02 43.76 3 66.67 20.47 25.78
4 68.88 54.72 56.39 4 66.67 25.98 30.66
5 61.73 64.11 63.83 5 66.67 26.38 31.01
6 51.53 74.44 71.75 6 63.64 31.10 34.84
7 50.26 75.87 72.86 7 63.64 34.25 37.63
8 39.03 85.76 80.26 8 63.64 38.19 41.11
9 23.21 93.88 85.57 9 57.58 50.39 51.22
11 21.94 94.36 85.84 11 57.58 52.36 52.96
13 21.17 94.97 86.29 13 51.52 56.30 55.75
15 11.22 98.23 88.00 15 45.45 70.08 67.25
16 10.46 98.33 88.00 16 36.36 73.62 69.34
17 2.81 99.66 88.27 17 18.18 83.07 75.61
24 2.81 99.76 88.36 24 18.18 85.43 77.70
25 2.81 99.80 88.39 25 18.18 85.83 78.05
31 0.26 99.97 88.24 31 12.12 92.13 82.93
37 0.00 99.97 88.21 37 6.06 94.88 84.67
NAFLD¼ nonalcoholic fatty liver disease.
Predictive Biomarkers for NAFLD 189years), whereas peak prevalence started to emerge after 50e60
years in women.
It has been demonstrated that the utilization of serum
biochemical markers or hepatic enzymes can effectively predict
NAFLD.15e18 NAFLD is the hepatic manifestation of metabolic
syndrome; therefore, the biomarkers that can predict NAFLD
should be predictive factors of metabolic syndrome too. The
biochemical markers and hepatic enzymes measured in NAFLD
include TG, fasting glucose, ALT, AST, AST/ALT ratio, T-Chol, the
homeostasis model assessment of insulin resistance, and C-reactive
protein.33e36 Among these, abnormal ALT levels are most often
investigated in the analysis of NAFLD, metabolic syndrome,
hyperglycemia, and other hepatic disorders.37,38 Nevertheless, ALT,
AST, and g-GT can all serve to be predictors for hepatic ﬁbrosis and
liver damage.39,40 In our study, both ALT and g-GT predict NAFLD
independently in both aging group groups. AST alone, when used as
predictor in the age group, had a marginal effect associated with
NAFLD. In the study concerning the sensitivity for NAFLD screening,Fig. 3. ROC curve of the predicted values from both estimated cardiovascular risk scores (MS
when FRS was used in both age groups, and also, the prediction model is nonsigniﬁcant in the
curve; ROC¼ receiver operating characteristic; MS¼metabolic scores; FRS¼ Framingham rour study population was larger as compared with the previous
studies.38,41e43 Interestingly, as compared with the younger group,
the differences of ALP, T-Chol, LDL, and UA between NAFLD and
non-NAFLD groups seemed to be less signiﬁcant in aging subjects.
Furthermore, in the aging group, the history of HTN and hyperlip-
idemia and systolic blood pressure showed no signiﬁcant difference
with and without NAFLD, and univariate logistic analysis reveals
that higher BMI (more than 30), the history of HTN and hyperlip-
idemia, postprandial blood sugar, T-Chol, LDL, and UA were unable
to predict NAFLD independently. The study by Kagansky et al.44
showed that the clinical features and biochemical markers
representative of metabolic syndrome were more obvious in the
younger group than in the aging group, which was similar to our
ﬁndings. They hypothesized it may be because of the undeﬁned
aging process leading to fatty inﬁltration or an irreversible
pathogenesis involved in the fatty liver formation in the elderly.44
We demonstrated a much better prediction of NAFLD with
traditional cardiovascular risk scores in the younger group.and FRS) in predicting NAFLD in different age groups. AUC was observed to be smaller
aging group (p¼ 0.09). NAFLD¼ nonalcoholic fatty liver disease; AUC¼ area under the
isk score.
C.-C. Liu et al.190Additionally, while compared with FRS, the AUC applied by using
MS shown to have a much larger predictive power with greater
speciﬁcity and classiﬁed proportion correctly. Therefore, these
biochemical markers and metabolic components can be applied
to the younger group as a useful screening test but may tend to
be less effective in the aging group. These ﬁndings suggest that
NAFLD per se, which correlates with some cardiovascular
morbidities, may be more preferentially inﬂuenced by pure
“metabolic” disorders (such as obesity and hyperlipidemia) rather
than other cardiovascular risk factors in FRS (as aging process and
smoking behavior). This ﬁnding provides a valuable ﬁnding that
can be used for future clinical screening of NAFLD in different age
groups.
Previous studies reported that AST/ALT ratio >1 is an effective
marker for more severe disease or liver cirrhosis,35 however, our
data showed that subjects with NAFLD tended to have lower AST/
ALT ratio, which is in line with another previous study.10 Yet, we
acknowledged that our cohort had very small percentage of
cirrhosis with generally less severe disease status and that such
ratio usage may have potential for screening of earlier stage
NAFLD with appropriate cutoff and worth further investigations.
In conclusion, our result suggested that the prevalence of NAFLD
in the Taiwanese, which was highly correlated with metabolic
abnormalities, was not high and had an age- and gender-based
difference in distribution. Clinical features typically related to
central obesity and altered biochemical markers were more
obvious in the younger as compared with the aging group. Finally,
the predictive model based on traditional cardiovascular risk scores
for efﬁcient screening of NAFLD may function better in the subjects
younger than 60 years and may serve as an important and
preventive therapeutic target in clinical practice.5. Limitations
Our study was not without limitations. Based on a single center
data collection, our observations were cross-sectional. The use of
biochemical markers and US in screening NAFLD is of wide clinical
application, but biochemical markers may vary by racial differences
(Eastern or Western countries), analytical methods, and usual
reference values used, and a relatively more subjective interpre-
tation for the ultrasonic results. In this study, data were analyzed
from the subjects who were more aware of their own health
condition and who attended health evaluation. Therefore, there
may be some bias in underestimating the true prevalence and
associated clinical manifestations of NAFLD in this analysis in
Taiwan. Aforementioned, the potential reading deviation associ-
ated with the interpretation of US should be taken into consider-
ation. For further investigations, these factors should be taken into
account, and a validation in translating such data into more robust
longitudinal outcomes may also be warranted.Acknowledgments
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